Genzyme Begins Phase 3 Pivotal Study of Clolar(R) and Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial.

0 Comments | M2 Presswire, September, 2006

M2 PRESSWIRE-7 September 2006-U.S. Equity News: Genzyme Begins Phase 3 Pivotal Study of Clolar(R) and Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:07092006 City of Industry, CA - Biotechnology industry alert provided by U.S.

Equity News. Genzyme Corporation (Nasdaq: GENZ) announced recently that the first patient has been treated in a new phase 3 clinical trial examining the safety and effectiveness of Clolar (clofarabine) in older patients with acute myelogenous leukemia (AML). This is the first pivotal clinical study of clofarabine in adult patients with AML, and is expected to provide substantial support for expanding the current product label. NutraCea (OTC BB:...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)